Pancreatic Cancer Research

ResearcherUniversity of ToyamaActive in the last 2 years

Nguyễn Duy Phan

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108280951. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 13

  1. Toyaburgine, a Synthetic N-Biphenyl-Dihydroisoquinoline Inspired by Related N,C-Coupled Naphthylisoquinoline Alkaloids, with High In Vivo Efficacy in Preclinic… Co-author DOI 10.1021/acschembio.4c00870↗
  2. Calliviminone A from Callistemon citrinus Induces PANC-1 Pancreatic Cancer Cell Death by Targeting the PI3K/Akt/mTOR Pathway. Co-author DOI 10.3390/plants14132074↗
  3. Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations. First author DOI 10.1021/acs.jmedchem.4c01141↗
  4. Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation. Co-author DOI 10.1021/acs.jmedchem.3c00394↗
  5. Nicolaioidesin C: An Antiausterity Agent Shows Promising Antitumor Activity in a Pancreatic Cancer Xenograft Mouse Model. Co-author DOI 10.1021/acs.jnatprod.3c00019↗
  6. Structure-activity relationship and mechanistic study on guggulsterone derivatives; Discovery of new anti-pancreatic cancer candidate. Co-author DOI 10.1016/j.bmc.2021.116563↗
  7. Design and synthesis of novel pipernonaline derivatives as anti-austerity agents against human pancreatic cancer PANC-1 cells. Co-author DOI 10.1016/j.bmc.2022.116963↗
  8. Abietane diterpenes from Abies spectabilis and their anti-pancreatic cancer activity against the MIA PaCa-2 cell line. Co-author DOI 10.1016/j.bmcl.2022.128723↗
  9. Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. Co-author DOI 10.3390/plants11192466↗
  10. GDP Induces PANC-1 Human Pancreatic Cancer Cell Death Preferentially under Nutrient Starvation by Inhibiting PI3K/Akt/mTOR/Autophagy Signaling Pathway. Co-author DOI 10.1002/cbdv.202100389↗
  11. A new anti-austerity agent, 4'-O-methylgrynullarin from Derris scandens induces PANC-1 human pancreatic cancer cell death under nutrition starvation via inhibi… Co-author DOI 10.1016/j.bmcl.2021.127967↗
  12. Chemical constituents of Thai Piper ribesoides and their antiausterity activities against the PANC-1 human pancreatic cancer cell line. Co-author DOI 10.1016/j.fitote.2021.104901↗
  13. Benzophenones from Betula alnoides with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line. Co-author DOI 10.1021/acs.jnatprod.1c00150↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suresh Awale · 13 shared papers, 2021–2025 · strength 2.25
  2. Juthamart Maneenet · 7 shared papers, 2022–2025 · strength 1.32
  3. Ashraf M. Omar · 8 shared papers, 2021–2023 · strength 1.23
  4. Tsutomu Fujii · 5 shared papers, 2022–2025 · strength 0.94
  5. Sijia Sun · 6 shared papers, 2021–2022 · strength 0.90
  6. Naoki Toyooka · 5 shared papers, 2022–2024 · strength 0.86
  7. Takuya Okada · 4 shared papers, 2022–2024 · strength 0.70
  8. Ahmed M. Tawila · 3 shared papers, 2021–2025 · strength 0.55
  9. Hung Hong Nguyen · 2 shared papers, 2025 · strength 0.49
  10. Dya Fita Dibwe · 2 shared papers, 2021–2022 · strength 0.28
  11. Gerhard Bringmann · 1 shared paper, 2025 · strength 0.25
  12. Takeyoshi Yamazaki · 1 shared paper, 2024 · strength 0.21
  13. Johji Imura · 1 shared paper, 2023 · strength 0.18
  14. Mitsuro Kanda · 1 shared paper, 2023 · strength 0.16
  15. Yuki Fujihashi · 1 shared paper, 2022 · strength 0.16
  16. Yûji Matsuya · 1 shared paper, 2022 · strength 0.15
  17. Aki Kohyama · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.